Section Arrow
Quote
SLGL.NASDAQ
- Sol-Gel Technologies Ltd
Quotes are at least 15-min delayed:2025/06/02 03:51 EDT
Last
 7.21
-0.0055 (-0.08%)
Day High 
7.341 
Prev. Close
7.2155 
1-M High
9 
Volume 
3.19K 
Bid
--
Ask
--
Day Low
7.189 
Open
7.189 
1-M Low
4.11 
Market Cap 
20.10M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 7.57 
20-SMA 7.45 
50-SMA 6.34 
52-W High 16.5 
52-W Low 3.34 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.80/-0.55
Enterprise Value
20.98M
Balance Sheet
Book Value Per Share
7.24
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
11.54M
Operating Revenue Per Share
0.45
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
INABIN8bio0.1446-0.0088-5.74%-- 
BLRXBioLineRx Ltd5.18+1.3891+36.64%-- 
IMNNImunon2.45+0.46+23.12%-- 
NCNANuCana plc0.03525-0.00175-4.73%-- 
MRNAModerna26.58-0.35-1.30%-- 
Quotes are at least 15-min delayed：2025/06/02 03:51 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includesSGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease andother rare keratosis-related indications such as PC, PPK and Olmsted.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.